2018 Q3 Form 10-Q Financial Statement
#000167479618000020 Filed on August 13, 2018
Income Statement
Concept | 2018 Q3 | 2018 Q2 | 2017 Q2 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $34.64K | $40.00K | $30.00K |
YoY Change | 15.47% | 33.33% | -25.0% |
% of Gross Profit | |||
Research & Development | |||
YoY Change | |||
% of Gross Profit | |||
Depreciation & Amortization | |||
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $34.64K | $40.00K | $30.00K |
YoY Change | 15.47% | 33.33% | -25.0% |
Operating Profit | -$34.64K | -$35.46K | -$34.60K |
YoY Change | 15.46% | 2.48% | -2.95% |
Interest Expense | -$8.940K | -$10.00K | -$10.00K |
YoY Change | -10.6% | 0.0% | 0.0% |
% of Operating Profit | |||
Other Income/Expense, Net | $0.00 | -$8.937K | -$8.937K |
YoY Change | -100.0% | 0.0% | 0.0% |
Pretax Income | -$43.58K | -$40.00K | -$40.00K |
YoY Change | 117.9% | 0.0% | 0.0% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$43.58K | -$40.00K | -$40.00K |
YoY Change | 117.9% | 0.0% | 0.0% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$17.80K | -$16.33K | -$16.33K |
COMMON SHARES | |||
Basic Shares Outstanding | 36.72M shares | 36.72M shares | 36.72M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2018 Q3 | 2018 Q2 | 2017 Q2 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cash & Equivalents | $0.00 | $0.00 | $0.00 |
Short-Term Investments | |||
Other Short-Term Assets | $0.00 | ||
YoY Change | |||
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $0.00 | $0.00 | $0.00 |
YoY Change | |||
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL ASSETS | |||
Total Short-Term Assets | $0.00 | $0.00 | $0.00 |
Total Long-Term Assets | $0.00 | $0.00 | $0.00 |
Total Assets | $0.00 | $0.00 | $0.00 |
YoY Change | |||
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $510.6K | $510.0K | $550.0K |
YoY Change | 0.13% | -7.27% | 3.77% |
Accrued Expenses | $1.448M | $1.410M | $1.250M |
YoY Change | 12.22% | 12.8% | 13.64% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $1.369M | $1.370M | $1.330M |
YoY Change | 2.17% | 3.01% | 1.53% |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $3.327M | $3.280M | $3.130M |
YoY Change | 5.63% | 4.79% | 6.46% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $3.327M | $3.280M | $3.130M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $3.327M | $3.280M | $3.130M |
YoY Change | 5.63% | 4.79% | 6.46% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$5.749M | -$5.705M | -$5.555M |
YoY Change | 3.2% | 2.72% | |
Common Stock | $36.72K | $36.72K | $36.72K |
YoY Change | 0.0% | 0.0% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$3.327M | -$3.280M | -$3.130M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $0.00 | $0.00 | $0.00 |
YoY Change |
Cashflow Statement
Concept | 2018 Q3 | 2018 Q2 | 2017 Q2 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$43.58K | -$40.00K | -$40.00K |
YoY Change | 117.9% | 0.0% | 0.0% |
Depreciation, Depletion And Amortization | |||
YoY Change | |||
Cash From Operating Activities | -$6.590K | -$10.00K | $0.00 |
YoY Change | -34.1% | -100.0% | |
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cash From Investing Activities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $0.00 | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 6.300K | 10.00K | 0.000 |
YoY Change | -37.0% | -100.0% | |
NET CHANGE | |||
Cash From Operating Activities | -6.590K | -10.00K | 0.000 |
Cash From Investing Activities | 0.000 | 0.000 | 0.000 |
Cash From Financing Activities | 6.300K | 10.00K | 0.000 |
Net Change In Cash | -290.0 | 0.000 | 0.000 |
YoY Change | |||
FREE CASH FLOW | |||
Cash From Operating Activities | -$6.590K | -$10.00K | $0.00 |
Capital Expenditures | |||
Free Cash Flow | |||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | ||
dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-06-30 | ||
dei |
Entity File Number
EntityFileNumber
|
000-15303 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
HST Global, Inc. | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Nevada | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
150 Research Drive, | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Hampton, | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
VA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
23666 | ||
dei |
City Area Code
CityAreaCode
|
757 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
766-6100 | ||
CY2018Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
36719854 | shares |
CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
0 | usd |
CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
291 | usd |
CY2018Q2 | us-gaap |
Assets Current
AssetsCurrent
|
0 | usd |
CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
291 | usd |
CY2018Q2 | us-gaap |
Assets
Assets
|
0 | usd |
CY2017Q4 | us-gaap |
Assets
Assets
|
291 | usd |
CY2018Q2 | us-gaap |
Bank Overdrafts
BankOverdrafts
|
2342 | usd |
CY2017Q4 | us-gaap |
Bank Overdrafts
BankOverdrafts
|
0 | usd |
CY2018Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
3588 | usd |
CY2017Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
4688 | usd |
CY2018Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
505959 | usd |
CY2017Q4 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
505959 | usd |
CY2018Q2 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
1050000 | usd |
CY2017Q4 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
990000 | usd |
CY2018Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
358755 | usd |
CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
340881 | usd |
CY2018Q2 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1363169 | usd |
CY2017Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1351369 | usd |
CY2018Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3283813 | usd |
CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3192897 | usd |
CY2018Q2 | us-gaap |
Liabilities
Liabilities
|
3283813 | usd |
CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
3192897 | usd |
CY2018Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2018Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2018Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2018Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2018Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2018Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36719854 | shares |
CY2018Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36719854 | shares |
CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36719854 | shares |
CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36719854 | shares |
CY2018Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
36720 | usd |
CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
36720 | usd |
CY2018Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
2384824 | usd |
CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
2384824 | usd |
CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-5705357 | usd |
CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-5614151 | usd |
CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3283813 | usd |
CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3192607 | usd |
CY2018Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
0 | usd |
CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
291 | usd |
CY2018Q2 | us-gaap |
Revenues
Revenues
|
0 | usd |
CY2017Q2 | us-gaap |
Revenues
Revenues
|
0 | usd |
us-gaap |
Revenues
Revenues
|
0 | usd | |
us-gaap |
Revenues
Revenues
|
0 | usd | |
CY2018Q2 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
30000 | usd |
CY2017Q2 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
30000 | usd |
us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
60000 | usd | |
us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
60000 | usd | |
CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5456 | usd |
CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4598 | usd |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13332 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
27606 | usd | |
CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
35456 | usd |
CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
34598 | usd |
us-gaap |
Operating Expenses
OperatingExpenses
|
73332 | usd | |
us-gaap |
Operating Expenses
OperatingExpenses
|
87606 | usd | |
CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-35456 | usd |
CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-34598 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-73332 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-87606 | usd | |
CY2018Q2 | us-gaap |
Interest Expense
InterestExpense
|
-8937 | usd |
CY2017Q2 | us-gaap |
Interest Expense
InterestExpense
|
-8937 | usd |
us-gaap |
Interest Expense
InterestExpense
|
-17874 | usd | |
us-gaap |
Interest Expense
InterestExpense
|
-17874 | usd | |
CY2018Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
-8937 | usd |
CY2017Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
-8937 | usd |
us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
-17874 | usd | |
us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
-17874 | usd | |
CY2018Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-44393 | usd |
CY2017Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-43535 | usd |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-91206 | usd | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-105480 | usd | |
CY2018Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2017Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.00 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-44393 | usd |
CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43535 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-91206 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-105480 | usd | |
CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.00 | |
CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.00 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.00 | ||
CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36719854 | shares |
CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36719854 | shares |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36719854 | shares | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36719854 | shares | |
us-gaap |
Profit Loss
ProfitLoss
|
-91206 | usd | |
us-gaap |
Profit Loss
ProfitLoss
|
-105480 | usd | |
fil |
Increase Decrease In Bank Overdraft Payable
IncreaseDecreaseInBankOverdraftPayable
|
2342 | usd | |
fil |
Increase Decrease In Bank Overdraft Payable
IncreaseDecreaseInBankOverdraftPayable
|
0 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1101 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
14822 | usd | |
us-gaap |
Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
|
60000 | usd | |
us-gaap |
Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
|
60000 | usd | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
17874 | usd | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
17874 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12091 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12784 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd | |
us-gaap |
Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
|
11800 | usd | |
us-gaap |
Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
|
12700 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
11800 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12700 | usd | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-291 | usd | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-84 | usd | |
CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
291 | usd |
CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
465 | usd |
CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
0 | usd |
CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
381 | usd |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt"><span style="font-size:10pt"><b>NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES </b></span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. (the "Company") was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. is an integrated Health and Wellness Biotechnology company that is developing and/or acquiring a network of Wellness Centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases. In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases.</p> | ||
us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K. </p> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> | ||
CY2017Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1351369 | usd |
us-gaap |
Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
|
11800 | usd | |
CY2018Q2 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1363169 | usd |